Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chondrosarcoma - Overview
Chondrosarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chondrosarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chondrosarcoma - Companies Involved in Therapeutics Development
Chondrosarcoma - Drug Profiles
Chondrosarcoma - Dormant Projects
Chondrosarcoma - Discontinued Products
Chondrosarcoma - Product Development Milestones
Featured News & Press Releases
Aug 15, 2022: European Medicines Agency grants Orphan Drug Desigtion to INBRX-109 for the treatment of chondrosarcoma
May 19, 2022: Inhibrx announces details of presentation at 2022 ASCO Annual Meeting
Feb 28, 2022: Inhibrx selects Genialis ResponderID for clinical optimization study of INBRX-109
Dec 01, 2021: Inhibrx receives FDA Orphan-Drug Desigtion for INBRX-109 in Chondrosarcoma
Nov 01, 2021: Inhibrx announces participation in upcoming scientific and investor conferences
Jun 21, 2021: Inhibrx initiates a potential registration-ebling phase 2 study of INBRX-109 in conventiol chondrosarcoma patients, updates data for ongoing phase 1 study and announces Amended loan agreement with Oxford
Jan 13, 2021: Inhibrx granted Fast Track Desigtion for INBRX-109 for the treatment of unresectable or metastatic conventiol chondrosarcoma patients
Nov 11, 2020: Inhibrx announces positive interim results from the phase 1 trial of INBRX-109 in chondrosarcoma patients
May 07, 2020: Haihe Pharmaceutical’s innovative drug IDH1 inhibitor obtains FDA clinical trial implied permission
Sep 20, 2019: Bayer highlights new data on Stivarga at ESMO 2019
Nov 18, 2016: Agios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Chondrosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Chondrosarcoma, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Chondrosarcoma - Dormant Projects, 2022
Chondrosarcoma - Discontinued Products, 2022